The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mestas, J.
Right arrow Articles by Strieter, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mestas, J.
Right arrow Articles by Strieter, R. M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
The Journal of Immunology, 2005, 175: 5351-5357.
Copyright © 2005 by The American Association of Immunologists

The Role of CXCR2/CXCR2 Ligand Biological Axis in Renal Cell Carcinoma1

Javier Mestas*, Marie D. Burdick*, Karen Reckamp*, Allan Pantuck{dagger}, Robert A. Figlin* and Robert M. Strieter2,*,{ddagger},§

* Department of Medicine, {dagger} Department of Urology, {ddagger} Department of Pathology, and § Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1786

Renal cell carcinoma (RCC) accounts for 3% of new cancer incidence and mortality in the United States. Studies in RCC have predominantly focused on VEGF in promoting tumor-associated angiogenesis. However, other angiogenic factors may contribute to the overall angiogenic milieu of RCC. We hypothesized that the CXCR2/CXCR2 ligand biological axis represents a mechanism by which RCC cells promote angiogenesis and facilitate tumor growth and metastasis. Therefore, we first examined tumor biopsies and plasma of patients with metastatic RCC for levels of CXCR2 ligands, and RCC tumor biopsies for the expression of CXCR2. The proangiogenic CXCR2 ligands CXCL1, CXCL3, CXCL5, and CXCL8, as well as VEGF were elevated in the plasma of these patients and found to be expressed within the tumors. CXCR2 was found to be expressed on endothelial cells within the tumors. To assess the role of ELR+ CXC chemokines in RCC, we next used a model of syngeneic RCC (i.e., RENCA) in BALB/c mice. CXCR2 ligand and VEGF expression temporally increased in direct correlation with RENCA growth in CXCR2+/+ mice. However, there was a marked reduction of RENCA tumor growth in CXCR2–/– mice, which correlated with decreased angiogenesis and increased tumor necrosis. Furthermore, in the absence of CXCR2, orthotopic RENCA tumors demonstrated a reduced potential to metastasize to the lungs of CXCR2–/– mice. These data support the notion that CXCR2/CXCR2 ligand biology is an important component of RCC tumor-associated angiogenesis and tumorigenesis.




This article has been cited by other articles:


Home page
Cancer Res.Home page
F. Hosoi, H. Izumi, A. Kawahara, Y. Murakami, H. Kinoshita, M. Kage, K. Nishio, K. Kohno, M. Kuwano, and M. Ono
N-myc Downstream Regulated Gene 1/Cap43 Suppresses Tumor Growth and Angiogenesis of Pancreatic Cancer through Attenuation of Inhibitor of {kappa}B Kinase {beta} Expression
Cancer Res., June 15, 2009; 69(12): 4983 - 4991.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Singh, M. Varney, and R. K. Singh
Host CXCR2-Dependent Regulation of Melanoma Growth, Angiogenesis, and Experimental Lung Metastasis
Cancer Res., January 15, 2009; 69(2): 411 - 415.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y.-H. Liu, C.-Y. Lin, W.-C. Lin, S.-W. Tang, M.-K. Lai, and J.-Y. Lin
Up-Regulation of Vascular Endothelial Growth Factor-D Expression in Clear Cell Renal Cell Carcinoma by CD74: A Critical Role in Cancer Cell Tumorigenesis
J. Immunol., November 1, 2008; 181(9): 6584 - 6594.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
E. C. Keeley, B. Mehrad, and R. M. Strieter
Chemokines as Mediators of Neovascularization
Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1928 - 1936.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. K. Raghuwanshi, M. W. Nasser, X. Chen, R. M. Strieter, and R. M. Richardson
Depletion of {beta}-Arrestin-2 Promotes Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer
J. Immunol., April 15, 2008; 180(8): 5699 - 5706.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
Z. B. Levashova, N. Sharma, O. A. Timofeeva, J. S. Dome, and A. O. Perantoni
ELR+-CXC Chemokines and Their Receptors in Early Metanephric Development
J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2359 - 2370.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.